WASHINGTON, Sept. 2 -- National Institutes of Health has issued a notice called: Prospective Grant of an Exclusive Patent License: Development and Commercialization of Mifepristone and Analogues To Treat Hypercortisolism-Related Insulin Resistance Disorders.
The notice was published in the Federal Register on Sept. 2 by Charles D. Niebylski, Director, Technology Advancement Office, National Institute of Diabetes and Digestive and Kidney Diseases.
Summary: The National Institute of Diabetes and Digestive and Kidney Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the invention embodied in the patents and patent applica...